Development and impact of prescription opioid abuse deterrent formulation technologies.

Background: Millions of patients are treated with opioid analgesics (OpAs) to relieve pain. Unfortunately, these medications are subject to abuse and/or unintended misuse. Abuse deterrent formulations (ADFs) represent an intervention strategy to decrease abuse/misuse without affecting patient access.

An iterative model for in vitro laboratory assessment of tamper deterrent formulations.

Background: In an effort to address the continuing problem of prescription opioid abuse, manufacturers are incorporating new technologies into formulations that are designed to deter product tampering and misuse. Standards for laboratory assessment of tamper deterrent properties of new formulations have not previously been developed.

Methods: Experimental designs were developed for the in vitro laboratory assessment of the tamper deterrent properties of reformulated oxycodone.